Abstract：
BACKGROUND: The purpose of this European multicenter study was to describe the general characteristics and risk factors of MRONJ lesions as well as their clinical diagnosis and management at different European Oral and Maxillofacial Surgery centers, in order to minimize selections biases and provide information about the epidemiology, etiopathogenesis, and the current trends in the treatment of MRONJ across Europe.
METHODS: The following data were registered for each patient: gender; age at MRONJ diagnosis; past medical history; indication for antiresorptive or antiangiogenic therapy; type of antiresorptive medication; local risk factor for MRONJ; MRONJ Stage; anatomic location and symptoms; treatment; surgical complications; recurrence.
RESULTS: A total of 537 patients (375 females, 162 males) with MRONJ were included. Statistically significant associations were found between patients with metastatic bone disease and recurrences (P < 0.0005) and between advanced MRONJ stages (stages 2 and 3) and recurrences (P < 0.005). Statistically significant associations were also found between male gender and recurrences (P < 0.05), and between MRONJ maxillary sites and recurrences (P < 0.0000005).
CONCLUSIONS: A longer mean duration of antiresorptive medications before MRONJ onset was observed in patients affected by osteoporosis, whereas a shorter mean duration was observed in all metastatic bone cancer patients, and in particular in those affected by prostate cancer with bone metastases or multiple myeloma. Surgery plays an important role for the management of MRONJ lesions.
METHODS: The following data were registered for each patient: gender; age at MRONJ diagnosis; past medical history; indication for antiresorptive or antiangiogenic therapy; type of antiresorptive medication; local risk factor for MRONJ; MRONJ Stage; anatomic location and symptoms; treatment; surgical complications; recurrence.
RESULTS: A total of 537 patients (375 females, 162 males) with MRONJ were included. Statistically significant associations were found between patients with metastatic bone disease and recurrences (P < 0.0005) and between advanced MRONJ stages (stages 2 and 3) and recurrences (P < 0.005). Statistically significant associations were also found between male gender and recurrences (P < 0.05), and between MRONJ maxillary sites and recurrences (P < 0.0000005).
CONCLUSIONS: A longer mean duration of antiresorptive medications before MRONJ onset was observed in patients affected by osteoporosis, whereas a shorter mean duration was observed in all metastatic bone cancer patients, and in particular in those affected by prostate cancer with bone metastases or multiple myeloma. Surgery plays an important role for the management of MRONJ lesions.
摘要：
背景：这项欧洲多中心研究的目的是描述MRONJ病变的一般特征和危险因素，以及不同欧洲口腔颌面外科中心的临床诊断和管理，为了最大限度地减少选择偏差并提供有关流行病学的信息，病因，以及目前欧洲MRONJ治疗的趋势。
方法：记录每位患者的以下数据：性别；MRONJ诊断年龄；既往病史；抗再吸收或抗血管生成治疗的指征；抗再吸收药物的类型；MRONJ的局部危险因素；MRONJ分期；解剖位置和症状；治疗；手术并发症；复发。
结果：共有537名患者（375名女性，包括162名男性）和MRONJ。在转移性骨病患者与复发之间（P<0.0005）以及晚期MRONJ分期（2期和3期）与复发之间（P<0.005）存在统计学上的显着关联。男性性别与复发之间也存在统计学上的显着关联（P<0.05）。MRONJ上颌部位和复发之间（P<0.0000005）。
结论：在受骨质疏松影响的患者中观察到在MRONJ发病前抗再吸收药物的平均持续时间较长，而在所有转移性骨癌患者中观察到较短的平均持续时间，尤其是那些患有骨转移或多发性骨髓瘤的前列腺癌患者。手术在MRONJ病变的治疗中起着重要作用。
方法：记录每位患者的以下数据：性别；MRONJ诊断年龄；既往病史；抗再吸收或抗血管生成治疗的指征；抗再吸收药物的类型；MRONJ的局部危险因素；MRONJ分期；解剖位置和症状；治疗；手术并发症；复发。
结果：共有537名患者（375名女性，包括162名男性）和MRONJ。在转移性骨病患者与复发之间（P<0.0005）以及晚期MRONJ分期（2期和3期）与复发之间（P<0.005）存在统计学上的显着关联。男性性别与复发之间也存在统计学上的显着关联（P<0.05）。MRONJ上颌部位和复发之间（P<0.0000005）。
结论：在受骨质疏松影响的患者中观察到在MRONJ发病前抗再吸收药物的平均持续时间较长，而在所有转移性骨癌患者中观察到较短的平均持续时间，尤其是那些患有骨转移或多发性骨髓瘤的前列腺癌患者。手术在MRONJ病变的治疗中起着重要作用。
